ETF Holdings Breakdown of MDGL

Stock Name	Madrigal Pharmaceuticals Inc
Ticker	MDGL(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US5588681057
LEI	549300CHIMT2EUSNJB60

MDGL institutional holdings

The following institutional investment holdings of MDGL have been identified

Date ETF ISIN/Name Num Shares Book value
2025-10-17 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 3,065 USD 1,345,229

2025-10-17 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 14,118 USD 6,196,390

2025-10-17 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 14,118 USD 6,196,390

2025-10-17 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 9,979 USD 4,379,783 1.2%

2025-10-17 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 74 USD 32,479 1.2%

Total = 41,354 USD 18,150,271
Book value of shares is calculated on the adjusted close price of each day (row).

Date	ETF ISIN/Name	Num Shares	Book value
2025-10-17	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	3,065	USD 1,345,229
2025-10-17	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	14,118	USD 6,196,390
2025-10-17	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	14,118	USD 6,196,390
2025-10-17	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	9,979	USD 4,379,783 1.2%
2025-10-17	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	74	USD 32,479 1.2%
Total =	41,354	USD 18,150,271

News associated with MDGL

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives $483.38 Consensus Target Price from Brokerages: Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the ten brokerages that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1 year target […] - 2025-09-17 02:42:46
Reviewing Madrigal Pharmaceuticals (NASDAQ:MDGL) and BioNxt Solutions (OTCMKTS:BNXTF): Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) and BioNxt Solutions (OTCMKTS:BNXTF – Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation. Profitability This table compares Madrigal Pharmaceuticals and BioNxt […] - 2025-08-28 04:46:53
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Consensus Recommendation of “Moderate Buy” from Brokerages: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) has received an average recommendation of “Moderate Buy” from the eight brokerages that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month price target […] - 2025-08-20 03:12:44
Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Down After Insider Selling: Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) gapped down before the market opened on Monday following insider selling activity. The stock had previously closed at $369.84, but opened at $354.56. Madrigal Pharmaceuticals shares last traded at $364.21, with a volume of 83,865 shares changing hands. Specifically, General Counsel Shannon T. Kelley sold […] - 2025-08-20 02:17:00
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Sells $3,652,000.00 in Stock: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) Director Kenneth Bate sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $365.20, for a total transaction of $3,652,000.00. Following the transaction, the director owned 2,627 shares of the company’s stock, […] - 2025-08-18 05:18:50
Cetera Investment Advisers Trims Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL): Cetera Investment Advisers reduced its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 1.7% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 2,832 shares of the biopharmaceutical company’s stock after selling 50 shares during the period. Cetera Investment Advisers’ holdings in Madrigal Pharmaceuticals were worth $938,000 as of its […] - 2025-08-13 04:49:04
1,003 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Bought by Blair William & Co. IL: Blair William & Co. IL bought a new position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 1,003 shares of the biopharmaceutical company’s stock, valued at approximately $332,000. Other hedge funds also […] - 2025-08-12 05:00:47
Zurcher Kantonalbank Zurich Cantonalbank Sells 291 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL): Zurcher Kantonalbank Zurich Cantonalbank trimmed its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 12.0% during the first quarter, HoldingsChannel reports. The firm owned 2,138 shares of the biopharmaceutical company’s stock after selling 291 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Madrigal Pharmaceuticals were worth $708,000 as of […] - 2025-08-07 04:26:51
Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Up on Strong Earnings: Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) gapped up before the market opened on Tuesday following a stronger than expected earnings report. The stock had previously closed at $312.11, but opened at $350.00. Madrigal Pharmaceuticals shares last traded at $330.70, with a volume of 156,412 shares traded. The biopharmaceutical company reported ($1.90) […] - 2025-08-07 02:12:57
Insider Selling: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Sells 1,000 Shares of Stock: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) Director Rebecca Taub sold 1,000 shares of the company’s stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $350.00, for a total transaction of $350,000.00. Following the transaction, the director owned 461,044 shares in the company, valued at $161,365,400. […] - 2025-07-24 05:51:01
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Sells $490,042.00 in Stock: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) Director Paul A. Friedman sold 1,400 shares of the firm’s stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $350.03, for a total value of $490,042.00. Following the completion of the sale, the director directly owned 187,164 […] - 2025-07-24 05:50:51
New York State Common Retirement Fund Boosts Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL): New York State Common Retirement Fund lifted its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 9.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 44,771 shares of the biopharmaceutical company’s stock after acquiring an additional 3,956 […] - 2025-07-18 06:22:45
Mutual of America Capital Management LLC Boosts Stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL): Mutual of America Capital Management LLC grew its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 0.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 11,263 shares of the biopharmaceutical company’s stock after purchasing an additional 31 shares during […] - 2025-07-18 05:49:00
D.A. Davidson & CO. Acquires 1,458 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL): D.A. Davidson & CO. grew its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 203.9% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 2,173 shares of the biopharmaceutical company’s stock after acquiring an additional 1,458 shares during the period. D.A. Davidson & CO.’s […] - 2025-07-10 05:25:03
First Horizon Advisors Inc. Grows Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL): First Horizon Advisors Inc. raised its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 38.9% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 157 shares of the biopharmaceutical company’s stock after purchasing an additional 44 shares during the period. First Horizon Advisors Inc.’s […] - 2025-07-08 05:08:55
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives $420.63 Consensus Price Target from Analysts: Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) have been given an average recommendation of “Moderate Buy” by the nine ratings firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The […] - 2025-07-04 02:40:48
QRG Capital Management Inc. Buys New Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL): QRG Capital Management Inc. bought a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) in the 1st quarter, according to its most recent disclosure with the SEC. The fund bought 726 shares of the biopharmaceutical company’s stock, valued at approximately $240,000. Other institutional investors also recently bought and sold shares of the company. […] - 2025-06-24 04:42:49
Head-To-Head Analysis: Madrigal Pharmaceuticals (NASDAQ:MDGL) and Larimar Therapeutics (NASDAQ:LRMR): Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) and Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, profitability and earnings. Profitability This table compares Larimar Therapeutics and Madrigal […] - 2025-06-12 03:09:35
Wellington Management Group LLP Has $2.52 Million Stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL): Wellington Management Group LLP lowered its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 9.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 8,172 shares of the biopharmaceutical company’s stock after selling 859 shares during the period. Wellington Management Group LLP’s holdings […] - 2025-06-06 05:04:52
Contrasting Madrigal Pharmaceuticals (NASDAQ:MDGL) and Adicet Bio (NASDAQ:ACET): Adicet Bio (NASDAQ:ACET – Get Free Report) and Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings and risk. Volatility & Risk Adicet Bio has a beta […] - 2025-05-21 03:01:02
MDGL Crosses Below Key Moving Average Level: In trading on Wednesday, shares of Madrigal Pharmaceuticals Inc (Symbol: MDGL) crossed below their 200 day moving average of $292.11, changing hands as low as $287.01 per share. Madrigal Pharmaceuticals Inc shares are currently trading down about 2.5% on the day. The chart bel - 2025-05-14 12:56:35
Canaccord Genuity Group Forecasts Strong Price Appreciation for Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock: Madrigal Pharmaceuticals (NASDAQ:MDGL – Free Report) had its price target raised by Canaccord Genuity Group from $394.00 to $420.00 in a research report released on Friday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. Several other research firms have also recently weighed in on MDGL. Citigroup increased their price target on […] - 2025-05-05 06:18:49
UBS Group Increases Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target to $458.00: Madrigal Pharmaceuticals (NASDAQ:MDGL – Free Report) had its target price boosted by UBS Group from $441.00 to $458.00 in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. Several other research firms have also recently issued reports on MDGL. Citigroup increased their […] - 2025-05-05 04:24:53
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Sold by Mariner LLC: Mariner LLC lowered its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 41.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,746 shares of the biopharmaceutical company’s stock after selling 1,252 shares during the quarter. Mariner LLC’s […] - 2025-05-02 05:08:50
CANADA LIFE ASSURANCE Co Increases Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL): CANADA LIFE ASSURANCE Co increased its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 81.1% during the fourth quarter, Holdings Channel.com reports. The firm owned 2,334 shares of the biopharmaceutical company’s stock after buying an additional 1,045 shares during the period. CANADA LIFE ASSURANCE Co’s holdings in Madrigal Pharmaceuticals were worth […] - 2025-04-30 05:44:14
1,467 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Purchased by Cerity Partners LLC: Cerity Partners LLC acquired a new position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 1,467 shares of the biopharmaceutical company’s stock, valued at approximately $453,000. Several other large investors have […] - 2025-04-23 05:38:50
Envestnet Asset Management Inc. Buys 334 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL): Envestnet Asset Management Inc. grew its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 2.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,001 shares of the biopharmaceutical company’s stock after buying an additional 334 shares during […] - 2025-04-23 04:20:54
Legal & General Group Plc Sells 312 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL): Legal & General Group Plc cut its stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 2.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 14,463 shares of the biopharmaceutical company’s stock after selling 312 shares during the quarter. Legal & General […] - 2025-04-22 05:45:20
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Bought by Barclays PLC: Barclays PLC grew its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 32.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 53,253 shares of the biopharmaceutical company’s stock after buying an additional 12,974 shares during the […] - 2025-04-21 06:00:46
Wells Fargo & Company MN Increases Stock Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL): Wells Fargo & Company MN grew its position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 19.1% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 34,923 shares of the biopharmaceutical company’s stock after acquiring an additional 5,604 shares during the period. Wells Fargo & Company MN’s holdings in Madrigal Pharmaceuticals were worth […] - 2025-04-17 05:44:53

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.